Taiwanese Biotech Firms Will Attend BioJapan 2026
Seventeen Taiwanese organizations will showcase innovation at the BioJapan conference in Yokohama this October.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Do you believe international biotech partnerships help expand your nation's innovation capabilities?
A delegation of seventeen Taiwanese biotech entities will attend the BioJapan 2026 conference from October 7 to 9, 2026. Led by the Biotechnology and Pharmaceutical Industries Promotion Office, the group aims to showcase regional advancements in biologics, CDMO, and cell therapy.
Why it matters
This mission highlights Taiwan's growing footprint in the global life sciences market, connecting local innovators with international partners. By leveraging established partnerships, the delegation seeks to expand the reach of Taiwanese biotechnology in the Japanese market.
Taiwan's biotech sector generated NT$830.1 billion in 2025, supported by 155 public companies with a combined market value of NT$1.59 trillion. These figures demonstrate the substantial scale of the regional industry currently entering international partnerships.
The players
Biotechnology and Pharmaceutical Industries Promotion Office
This government-affiliated entity leads and coordinates the international promotion of Taiwan's life sciences sector.
Steminent
This biotech firm is currently developing regenerative medicine therapies including Stemchymal.
UnicoCell
This company focuses on cell therapy innovation and has reached advanced stages of clinical trial enrollment.
Bora Biologics
This organization specializes in contract development and manufacturing for the global biologics industry.
TFBS Bioscience
This bioscience firm provides testing and development services to support global pharmaceutical research.
The details
Participating companies will operate from the Taiwan Pavilion at Booth No. D-26 to highlight specific developments like the commercialization of RAPClot technology and various cell therapy applications. Key updates include progress on Stemchymal by Steminent, Phase III patient enrollment for UnicoCell, and new trial approvals for GWO XI Stem Cell.
Timeline
The 2025 fiscal year saw the sector generate NT$830.1 billion.
BioJapan 2026 is scheduled for October 7 to 9, 2026.
A networking reception is set for October 8, 2026, from 4:00 PM to 5:00 PM.
The Tech Race
This presence at BioJapan 2026 follows the strategic international outreach patterns established by the Biotechnology and Pharmaceutical Industries Promotion Office. It highlights Taiwan's shift toward aggressive global market integration to challenge established regional competitors in the biologics space.
For industry stakeholders, this delegation provides opportunities to access new cell therapy and biologics technologies that may eventually reach global clinical markets. The partnerships formed could lead to more competitive pricing and wider availability of advanced medical treatments for patients.
The takeaway
The active participation of Taiwanese firms in international conferences indicates a concerted effort to scale domestic innovation globally. These partnerships are essential for integrating regional research advancements into the international life sciences supply chain.
Further reading
Learn more about the latest innovations and market trends at the Biotech section.
More information
For more information on the sector, visit the Biotech industry information portal.
Live Poll
Do you believe international biotech partnerships help expand your nation's innovation capabilities?
